



SHAREABLE PDF

AGORA

RESEARCH LETTER

ERJ European Respiratory Journal Eur Respir J 0903-1936/1399-3003 European Respiratory Society 10.1183/13993003.01234-2020 ERJ-01234-2020 AGORA RESEARCH LETTER

A predictive model for disease progression in non-severely ill patients with coronavirus disease 2019. Ji M, Mengyao J, Yuan L, Shen W, Lv J, Li Y, Chen J, Zhu C, Liu B, Liang Z, Lin Q, Xie W, Li M, Chen Z, Lu X, Ding Y, An P, Zhu S, Gao M, Ni H, Hu L, Shi G, Shi L, Dong W. *Respiratory Research* 2020; 21:1234-1245. doi:10.1183/20445312.2020.01234-2020

Ji Mengyao^{1,10}, Yuan Lei^{2,10}, Shen Wei^{3,4,10}, Lv Junwei^{3,4}, Li Yong^{5,10}, Chen Jia^{3,4}, Zhu Chaonan^{3,4}, Liu Bo^{3,4}, Liang Zhenzhen⁶, Lin Qiang^{3,4}, Xie Wenjie⁷, Li Ming², Chen Zhifan⁸, Lu Xuefang⁹, Ding Yi Juan¹, An Ping¹, Zhu Sheng^{3,4}, Gao Mengting², Ni Hao^{3,4}, Hu Lanhua⁹, Shi Guanglei^{3,4}, Shi Lei^{3,4,11}, Dong Weiguo^{1,11},

¹Dept of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China. ²Dept of Information Center, Renmin Hospital of Wuhan University, Wuhan, China. ³Shanghai Key Laboratory of Artificial Intelligence for Medical Image and Knowledge Graph, Shanghai, China. ⁴Hangzhou YITU Healthcare Technology Co., Ltd, Hangzhou, China. ⁵Dept of Radiology, Suining Central Hospital, Suining, China. ⁶Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. ⁷Dept of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China. ⁸Dept of Radiology, Affiliated Hospital of Chengdu University, Chengdu, China. ⁹Dept of Radiology, Renmin Hospital of Wuhan University, Wuhan, China. ¹⁰Mengyao Ji, Lei Yuan, Wei Shen and Yong Li contributed equally to this paper. ¹¹Weiguo Dong and Lei Shi contributed equally to this article as lead authors and supervised the work.

Correspondence: Weiguo Dong, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan City, Wuhan 430060, China. E-mail: weiguodong_66@163.com 20202020560160320201005202020

To the Editor:

Over the past 3 months, coronavirus disease 2019 (COVID-19) has emerged across China and developed into a worldwide outbreak [1]. The disease has caused varying degrees of illness. The proportion of patients with COVID-19 with non-severe illness was 84.3% on admission, and severe cases accounted for 15.7% [2]. Most of the non-severe pneumonia patients would gradually alleviate and be cured with treatment, while others would rapidly progress to severe illness, which has a poor prognosis [3, 4]. As recently reported, the cumulative risk of the composite end-point was 3.6% in all COVID-19 patients, and the cumulative risk was 20.6% for severe illness [2].